{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:46:01Z","timestamp":1740167161258,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40120-022-00374-4","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T04:02:27Z","timestamp":1655438547000},"page":"1253-1268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment Status and Healthcare Cost Trends for Patients with Multiple Sclerosis in Japan: A Claims Database Analysis"],"prefix":"10.1007","volume":"11","author":[{"given":"Izumi","family":"Kawachi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Otaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"374_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1177\/1352458507084264","volume":"14","author":"H Tremlett","year":"2008","unstructured":"Tremlett H, Zhao Y, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler. 2008;14:314\u201324.","journal-title":"Mult Scler"},{"key":"374_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1136\/jnnp-2012-304333","volume":"85","author":"A Scalfari","year":"2014","unstructured":"Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85:67\u201375.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 1","key":"374_CR3","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","volume":"9","author":"G Giovannoni","year":"2016","unstructured":"Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Journal Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9(Suppl 1):S5\u201348.","journal-title":"Mult Scler Relat Disord"},{"key":"374_CR4","unstructured":"MS International Fundation. Atlas of MS 3rd edition. 2020. https:\/\/www.msif.org\/wp-content\/uploads\/2020\/10\/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf. Accessed 1 Nov 2021."},{"key":"374_CR5","unstructured":"National Murtiple Sclerosis Society. Disease-modifying therapies for MS. July 2021. https:\/\/www.nationalmssociety.org\/NationalMSSociety\/media\/MSNationalFiles\/Brochures\/Brochure-The-MS-Disease-Modifying-Medications.pdf. Accessed 1 Nov 2021."},{"key":"374_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000444019","volume":"46","author":"S Eskandarieh","year":"2016","unstructured":"Eskandarieh S, Heydarpour P, Minagar A, Pourmand S, Sahraian MA. Multiple sclerosis epidemiology in East Asia, South East Asia and South Asia: a systematic review. Neuroepidemiology. 2016;46:209\u201321.","journal-title":"Neuroepidemiology"},{"key":"374_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/cen3.12411","volume":"8","author":"M Ogino","year":"2017","unstructured":"Ogino M, Okamoto S, Ohta H, et al. Prevalence, treatments and medical cost of multiple sclerosis in Japan based on analysis of a health insurance claims database. Clin Exp Neuroimmunol. 2017;8:318\u201326.","journal-title":"Clin Exp Neuroimmunol"},{"key":"374_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/1352458508098372","volume":"15","author":"M Osoegawa","year":"2009","unstructured":"Osoegawa M, Kira J, Fukazawa T, et al. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years. Mult Scler. 2009;15:159\u201373.","journal-title":"Mult Scler"},{"key":"374_CR9","doi-asserted-by":"crossref","unstructured":"Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet. 1998;352:1491\u20131497.","DOI":"10.1016\/S0140-6736(98)10039-9"},{"key":"374_CR10","doi-asserted-by":"crossref","unstructured":"La Mantia L, Vacchi L, Rovaris M, et al. Interferon beta for secondary progressive multiple sclerosis. Cochrane Database Syst Rev. 2012;1:CD005181.","DOI":"10.1002\/14651858.CD005181.pub3"},{"key":"374_CR11","unstructured":"Treatment Guidelines for Multiple Sclerosis Development Committee. Treatment guidelines for multiple sclerosis. Tokyo: Igaku-Shoin; 2010. (in Japanese)."},{"key":"374_CR12","unstructured":"Multiple Sclerosis and Neuromyelitis Optica Guideline Development Committee. Guidelines for multiple sclerosis and neuromyelitis optica. Tokyo: Igaku-Shoin; 2017. (in Japanese)."},{"key":"374_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/cen3.12299","volume":"7","author":"M Ogino","year":"2016","unstructured":"Ogino M, Kawachi I, Otake K, et al. Current treatment status and medical cost for multiple sclerosis based on analysis of a Japanese claims database. Clin Exp Neuroimmunol. 2016;7:158\u201367.","journal-title":"Clin Exp Neuroimmunol"},{"key":"374_CR14","first-page":"279","volume":"55","author":"M Ishii","year":"2012","unstructured":"Ishii M. DRG\/PPS and DPC\/PDPS as prospective payment systems. Japan Med Assoc J. 2012;55:279\u201391.","journal-title":"Japan Med Assoc J"},{"key":"374_CR15","unstructured":"Central Social Insurance Medical Council, Ministry of Health, Labor and Welfare. [Estimated scale of DPC hospitals and preparatory hospitals (as of April 1, 2020)]. https:\/\/www.mhlw.go.jp\/content\/12404000\/000640465.pdf. Accessed 26 Oct 2021. (in Japanese)."},{"key":"374_CR16","unstructured":"Ministry of Health, Labor and Welfare. Statistical classification of diseases and cause of death 2013. http:\/\/www.mhlw.go.jp\/toukei\/sippei\/. Accessed 23 Dec 2020. Japanese."},{"key":"374_CR17","unstructured":"Pyenson BS, Tomicki S. Multiple sclerosis: new perspectives on the patient journey: 2019 Update. USA Report, Milliman. 2019. https:\/\/us.milliman.com\/en\/insight\/multiple-sclerosis-new-perspectives-on-the-patient-journey-2019-update. Accessed 20 Mar 2019."},{"key":"374_CR18","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1093\/brain\/awm027","volume":"130","author":"T Matsuoka","year":"2007","unstructured":"Matsuoka T, Matsushita T, Kawano Y, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain. 2007;130:1206\u201323.","journal-title":"Brain"},{"key":"374_CR19","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00415-015-7637-3","volume":"262","author":"L Piccolo","year":"2015","unstructured":"Piccolo L, Kumar G, Nakashima I, et al. Multiple sclerosis in Japan appears to be a milder disease compared to the UK. J Neurol. 2015;262:831\u20136.","journal-title":"J Neurol"},{"key":"374_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048592","volume":"7","author":"S Yoshimura","year":"2012","unstructured":"Yoshimura S, Isobe N, Yonekawa T, et al. Genetic and infectious profiles of Japanese multiple sclerosis patients. PLoS ONE. 2012;7: e48592.","journal-title":"PLoS ONE"},{"key":"374_CR21","unstructured":"Japan Intractable Diseases Information Center. Information on the financial aid for the patients with the designated incurable diseases. http:\/\/www.nanbyou.or.jp\/entry\/5460. Accessed Dec 25, 2020. (in Japanese)."},{"key":"374_CR22","unstructured":"Costello K, Halper J, Kalb R, Skutnik L, Rapp, R. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence. A Consensus Paper by the Multiple Sclerosis Coalition. 2020. http:\/\/www.nationalmssociety.org\/NationalMSSociety\/media\/MSNationalFiles\/Brochures\/DMT_Consensus_MS_Coalition.pdf. Accessed Dec 25, 2020."},{"key":"374_CR23","first-page":"s159","volume":"22","author":"FM Hart","year":"2016","unstructured":"Hart FM, Bainbridge J. Current and emerging treatment of multiple sclerosis. Am J Manag Care. 2016;22:s159-170.","journal-title":"Am J Manag Care"},{"key":"374_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","volume":"321","author":"JWL Brown","year":"2019","unstructured":"Brown JWL, Coles A, Horakova D, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321:175\u201387.","journal-title":"JAMA"},{"key":"374_CR25","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;90:777\u201388.","journal-title":"Neurology"},{"key":"374_CR26","doi-asserted-by":"crossref","unstructured":"Kuroiwa Y, Igata A, Itahara K, Koshijima S, Tsubaki T. Nationwide survey of multiple sclerosis in Japan. Clinical analysis of 1,084 cases. Neurology. 1975;25:845\u201351.","DOI":"10.1212\/WNL.25.9.845"},{"key":"374_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nrneurol.2017.33","volume":"13","author":"RA Marrie","year":"2017","unstructured":"Marrie RA. Comorbidity in multiple sclerosis: implications for patient care. Nat Rev Neurol. 2017;13:375\u201382.","journal-title":"Nat Rev Neurol"},{"key":"374_CR28","doi-asserted-by":"crossref","unstructured":"Wijnands JMA, Kingwell E, Zhu F, et al. Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study. Lancet Neurol. 2017;16:445\u201351.","DOI":"10.1016\/S1474-4422(17)30076-5"},{"key":"374_CR29","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1177\/1352458518783662","volume":"25","author":"JM Wijnands","year":"2019","unstructured":"Wijnands JM, Zhu F, Kingwell E, et al. Five years before multiple sclerosis onset: phenotyping the prodrome. Mult Scler. 2019;25:1092\u2013101.","journal-title":"Mult Scler"},{"key":"374_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3111\/13696998.2015.1086362","volume":"19","author":"J Ruutiainen","year":"2016","unstructured":"Ruutiainen J, Viita AM, Hahl J, Sundell J, Nissinen H. Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis. J Med Econ. 2016;19:21\u201333.","journal-title":"J Med Econ"},{"key":"374_CR31","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12913-016-1352-3","volume":"16","author":"NL da Silva","year":"2016","unstructured":"da Silva NL, Takemoto MLS, Damasceno A, et al. Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study. BMC Health Serv Res. 2016;16:102.","journal-title":"BMC Health Serv Res"},{"key":"374_CR32","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3111\/13696998.2013.807267","volume":"16","author":"K Karampampa","year":"2013","unstructured":"Karampampa K, Gustavsson A, van Munster ET, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: the costs and utilities of MS patients in the Netherlands. J Med Econ. 2013;16:939\u201350.","journal-title":"J Med Econ"},{"key":"374_CR33","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1177\/1352458513488230","volume":"19","author":"AJ Palmer","year":"2013","unstructured":"Palmer AJ, Colman S, O\u2019Leary B, et al. The economic impact of multiple sclerosis in Australia in 2010. Mult Scler. 2013;19:1640\u20136.","journal-title":"Mult Scler"},{"key":"374_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1586\/14737167.2015.1067141","volume":"15","author":"E Stawowczyk","year":"2015","unstructured":"Stawowczyk E, Malinowski KP, Kawalec P, Mo\u0107ko P. The indirect costs of multiple sclerosis: systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2015;15:759\u201386.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00374-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00374-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00374-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T15:03:25Z","timestamp":1659107005000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00374-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["374"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00374-4","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"type":"print","value":"2193-8253"},{"type":"electronic","value":"2193-6536"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"3 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}